BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible for all.
BillionToOne is the only genetic testing platform that accurately and efficiently detects and measures disease at the molecular level.
BillionToOne was founded in 2016 by Oguzhan Atay and David Tsao. The company is headquartered in Palo Alto, California.
BillionToOne has invented the patent-pending QCTTM molecular counter platform which accurately count DNA molecules to the single-count level. BillionToOne’s cancer diagnostic test lowers the limit of detection for gene amplifications by 10x so that these hallmarks of cancer are detected earlier.
BillionToOne’s first product, UNITY, is the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF) and spinal muscular atrophy (SMA) through a single sample of the mother’s blood.
BillionToOne's molecular counting technology increases the resolution of disease detection using cell-free DNA by over 1000-fold. This technology is at the core of the Company's products.
BillionToOne is backed by Adams Street Partners, Hummingbird Ventures, Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Y Combinator, Libertus Capital, Pacific 8 Ventures, Civilization Ventures, and others. The company raised $125M in Series C round on Mar 30, 2022. This brings BillionToOne's total funding to $212.4M to date.